Background Patients with cancer with hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection are excluded from many cancer clinical trials of immune checkpoint inhibitors (ICIs) …

More patients with chronic hepatitis B and C infection are being exposed to immune
checkpoint inhibitors (ICIs), but the safety and efficacy of ICIs in patients with chronic viral …

Background: Immune checkpoint inhibitor (ICI) therapy is now administered to patients with
advanced cancers. However, the safety and efficacy of ICIs in cancer patients with hepatitis …

Abstract Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line
treatment in various types of previously untreatable malignancies, while limited evidence is …

Introduction Patients with cancer and hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection are underrepresented in several clinical trials testing immune checkpoint inhibitors …

Background: Cancer patients with hepatitis B or C virus (HBV/HCV) infection are commonly
seen in clinical practice, however, the data of safety and efficacy of immune checkpoint …

Background Despite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with
a viral hepatitis have been excluded from clinical trials because of safety concerns. The …

Abstracts Background Patients with chronic viral infections including human
immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk …

Background Immunotherapy shows promise as a treatment option for various cancers.
However, there is growing concern over potential complications from hepatitis B virus (HBV) …

Background. Immune checkpoint inhibitors (ICIs) have changed the situation of tumor
therapy in recent years. However, for security reasons, those special populations are often …